Institut Jules Bordet

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

Retrieved on: 
Wednesday, January 17, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Retail, Genetics, Science, Clinical Trials, Université catholique de Louvain, Molecular imaging, Tumor microenvironment, OncoDNA, Patient, Neoplasm, HUB, DNA, Multimedia, Circulating tumor DNA, RNA, Liquid biopsy, Education minister, PDC, Cancer, Breast cancer, Institut Jules Bordet, B cell, Safety, ULB, CRC, Clinical trial, ATMP, Colorectal cancer, Pharmaceutical industry

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

Key Points: 
  • PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.
  • Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma.
  • View the full release here: https://www.businesswire.com/news/home/20240117630349/en/
    The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
  • Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy.

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Retrieved on: 
Thursday, January 5, 2023
Immunosuppression, Cancer, Lead, GPCR, G protein-coupled receptor, Pharmacokinetics, Drug discovery, PGE2, Therapy, Hope, EP4, Trial of the century, Patient, Gq alpha subunit, Safety, Immune system, IO, Institut Jules Bordet, Curie Institute (Paris), Neoplasm, Pharmaceutical industry, Vaccine

In preclinical studies, the asset demonstrated strong anti-tumor effects and synergies with immune checkpoint inhibitors in multiple models.

Key Points: 
  • In preclinical studies, the asset demonstrated strong anti-tumor effects and synergies with immune checkpoint inhibitors in multiple models.
  • The Phase I study, named EPRAD, is a multi-center, open-label study that will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DT-9081 in adult patients with advanced, recurrent or metastatic solid tumors who have failed standard of care therapies.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The successful initiation of this first-in-human study is a significant milestone for Domain.
  • By blocking the EP4 receptor, I believe that DT-9081 has the potential to address this challenge and offer new hope for patients.

Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Health, Other Health, Radiology, Pharmaceutical, Oncology, Other Science, University, Research, Medical Devices, Education, General Health, Hospitals, Science, Neutron, Institut Jules Bordet, Cancer, Heart, Commitment, Teaching hospital, Radiation, NT, Institute, Jules Bordet, Technology, Inclusion, CEO, MIT, Efficiency, Bordet-Gengou agar, Letter, Graphite-moderated reactor, Research, Adoption, Erasmus, IJB, Queen Fabiola of Belgium, Solidarity, BNCT, Diversity, Caregiver, Education, Partnership, IAEA, Intention, Patient, National Letter of Intent, Multimedia, ULB, Brussels, Therapy, Medical imaging, Lithium

nuBeam is the worlds safest and most powerful accelerator-based neutron source designed specifically for the hospital environment.

Key Points: 
  • nuBeam is the worlds safest and most powerful accelerator-based neutron source designed specifically for the hospital environment.
  • With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients.
  • Neutron Therapeutics is a leading provider of boron neutron capture therapy (BNCT) systems for use in the radiation treatment of cancer patients.
  • Neutron Therapeutics' flagship product, the nuBeam therapy platform, is an accelerator-based, in-hospital neutron source to replace the previously required nuclear reactor.

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)

Retrieved on: 
Tuesday, June 21, 2022
Population, Beti, Ipilimumab, ADP, Merck, BRCA, Clinical trial, Talazoparib, BET, University, Targeted therapy, ASCO, RAD51, Disorder, GLOBE, Neoplasm, Pembrolizumab, Therapy, Poster, Institute, CEO, Breast, National, DNA, Mutation, 2021 Essex County Council election, National Cancer Institute, MCRPC, Astellas Pharma, University of California, San Francisco, HER2, PR, Nivolumab, TNBC, Ovarian cancer, Parpi, Adult, Patient, Woman, BMS, Breast cancer, Zenith, PARP, Institut Jules Bordet, Cancer, Trial of the century, Conversation, Program, Pfizer, Prognosis, GRASP, Pharmaceutical industry, EU

The poster can be viewed on Zenith Epigenetics website ( Poster ) and the discussion can be viewed on the ASCO website ( Discussion ).

Key Points: 
  • The poster can be viewed on Zenith Epigenetics website ( Poster ) and the discussion can be viewed on the ASCO website ( Discussion ).
  • Zenith has expanded the Phase 2 trial to continue to evaluate the combination in an additional 120 mTNBC patients ( NCT03901469 ).
  • The combination regimen of ZEN-3694 + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need.
  • Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib), conducted in collaboration with Pfizer and Newsoara Biopharma.

Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Retrieved on: 
Tuesday, June 7, 2022
Oncology, Cairo University, Breast cancer, Institut Jules Bordet, Research, European Society for Medical Oncology, Society, Control, Doctor of Philosophy, Newcastle upon Tyne, ESMO, CEO, Medical degree, Cancer, ASCO, ADC, University, Therapy, American Society of Clinical Oncology, MD, Pharmaceutical industry, Emergence

Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (CMO), as of 6 June 2022.

Key Points: 
  • Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (CMO), as of 6 June 2022.
  • Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a French multinational pharmaceutical company where he was Head of Oncology Early Clinical Development.
  • Jack Elands, CEO of Emergence Therapeutics, commented: I am delighted to welcome Hatem to Emergence as our Chief Medical Officer.
  • Hatem Azim commented: Emergence Therapeutics is on the frontier of developing novel, highly selective ADCs for the treatment of hard-to-treat cancers.

Nordic Nanovector appoints experienced biotech executive Pierre Dodion MD as Chief Medical Officer

Retrieved on: 
Monday, November 8, 2021
Society, UCB, University, Pharmaceutical physician, Saint Joseph University, CMO, Novartis, CEO, MBA, Institut Jules Bordet, Roche, ARIAD Pharmaceuticals, Lilotomab, American Society of Clinical Oncology, Non-Hodgkin lymphoma, Association, Letrozole, OSE, Company, Sunitinib, Free University of Brussels (1834–1969), Sanofi, NANO, Pierre, Patient, Institute, Fine chemical, Pharmaceutical industry

OSLO, Norway, Nov. 8, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Pierre Dodion MD as Chief Medical Officer (CMO).

Key Points: 
  • OSLO, Norway, Nov. 8, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Pierre Dodion MD as Chief Medical Officer (CMO).
  • Dr Dodion joins Nordic Nanovector from Immunooncology Partners, a consultancy he founded to support biotech companies in clinical development, medical affairs and business development activities.
  • Erik Skullerud, CEO of Nordic Nanovector,commented: "We're delighted to bring Pierre on board as Chief Medical Officer, following a successful consulting relationship.
  • Pierre Dodion, incoming CMO of Nordic Nanovector, said: "It's great to be joining Nordic Nanovector at such a pivotal time for the company.

Nordic Nanovector appoints experienced biotech executive Pierre Dodion MD as Chief Medical Officer

Retrieved on: 
Monday, November 8, 2021
Society, UCB, University, Pharmaceutical physician, Saint Joseph University, CMO, Novartis, CEO, MBA, Institut Jules Bordet, Roche, ARIAD Pharmaceuticals, Lilotomab, American Society of Clinical Oncology, Non-Hodgkin lymphoma, Association, Letrozole, OSE, Company, Sunitinib, Free University of Brussels (1834–1969), Sanofi, NANO, Pierre, Patient, Institute, Fine chemical, Pharmaceutical industry

OSLO, Norway, Nov. 8, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Pierre Dodion MD as Chief Medical Officer (CMO).

Key Points: 
  • OSLO, Norway, Nov. 8, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Pierre Dodion MD as Chief Medical Officer (CMO).
  • Dr Dodion joins Nordic Nanovector from Immunooncology Partners, a consultancy he founded to support biotech companies in clinical development, medical affairs and business development activities.
  • Erik Skullerud, CEO of Nordic Nanovector,commented: "We're delighted to bring Pierre on board as Chief Medical Officer, following a successful consulting relationship.
  • Pierre Dodion, incoming CMO of Nordic Nanovector, said: "It's great to be joining Nordic Nanovector at such a pivotal time for the company.

OncLive® Names the 2020 Class of Giants of Cancer Care®

Retrieved on: 
Thursday, September 17, 2020
Hospitals, Health, Surgery, Oncology, Institut Jules Bordet, Oncology, Martine Piccart, Health in Belgium, OncLive®, Giants of Cancer Care®

OncLive, the nations leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care class of inductees.

Key Points: 
  • OncLive, the nations leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care class of inductees.
  • The members of the 2020 class of Giants of Cancer Care are oncology legends who have made remarkable differences in the cancer care landscape, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of OncLive.
  • This years Giants of Cancer Care inductees by award category are:
    Breast Cancer Martine J. Piccart, M.D., Ph.D., Universit Libre de Bruxelles and Jules Bordet Institute.
  • Out of 818 nominations, only 15 oncologists were selected to the prestigious 2020 class of Giants of Cancer Care.

Institut Jules Bordet Invests in Elekta's Latest Cancer Treatment Technology

Retrieved on: 
Monday, January 20, 2020
Medicine, Radiobiology, Branches of biology, Health, Radiation therapy, Accelerator physics, Medical physics, Elekta, Linear particle accelerator, Institut Jules Bordet, Radiosurgery

Elekta's Head of Region Europe, Renato Leite, says: "We are proud to strengthen our long-standing relationship with the Bordet Institute, which is devoted entirely to patients affected by cancer.

Key Points: 
  • Elekta's Head of Region Europe, Renato Leite, says: "We are proud to strengthen our long-standing relationship with the Bordet Institute, which is devoted entirely to patients affected by cancer.
  • As it prepares to move to its New Bordet Institute in 2021, we are excited to be providing the most modern radiotherapy treatment solutions available so the Institute can offer its cancer patients personalized precision radiation medicine."
  • The comprehensive cancer center is gearing up for its new cancer clinic with an investment in state-of-the-art technology and upgrades to existing devices.
  • When all the solutions will have been deployed the Jules Bordet Institute will be Belgium's the largest single radiation therapy site with four Elekta linacs, one Unity MR-Linac and one Leksell Gamma Knife.

Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer

Retrieved on: 
Tuesday, June 19, 2018
Cancer, Cancer treatments, Clinical medicine, Medicine, Ribbon symbolism, Breast cancer, Neoadjuvant therapy, Institut Jules Bordet, Adjuvant therapy, Metastatic breast cancer

Natera will analyze approximately 300 plasma specimens prospectively collected and banked from 80 patients diagnosed with non-metastatic breast cancer, who all received neoadjuvant chemotherapy followed by surgery, and who were then monitored for recurrence with serial imaging.

Key Points: 
  • Natera will analyze approximately 300 plasma specimens prospectively collected and banked from 80 patients diagnosed with non-metastatic breast cancer, who all received neoadjuvant chemotherapy followed by surgery, and who were then monitored for recurrence with serial imaging.
  • "We are pleased to work with Natera to explore this exciting new approach for evaluating treatment response in the neoadjuvant setting," Dr. Ignatiadis said.
  • This is the third breast cancer collaboration Natera has announced in the past 18 months.
  • For more than 75 years, Institut Jules Bordet has been offering its patients diagnostic and therapeutic strategies at the leading edge of progress to prevent, detect, and actively fight cancer.